Aurinia is up 25% on voclosporin win; expects net revenue at $65K per patient

Jan. 25, 2021 10:52 AM ETAurinia Pharmaceuticals Inc. (AUPH)AUPHBy: Dulan Lokuwithana, SA News Editor55 Comments
  • Aurinia Pharmaceuticals (NASDAQ:AUPH) has surged ~24.5% in response to its late Friday announcement of FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis.
  • In a conference call arranged to discuss the regulatory win, the company estimated that the average annualized net revenue from the treatment could be ~$65K per patient after accounting for rebates, channel discounts, and anticipated patient adherence.
  • Considered as a rare disease lupus nephritis affects nearly a third of people diagnosed with systemic lupus erythematosus estimated at ~200 – 300K patients in the U.S. alone.
  • The company has already completed the pre-approval information exchange with more than 50 payers covering two-thirds of commercially insured lives.
  • With the in-person and virtual launch of voclosporin taking place in 2021, Aurinia projects a peak annual U.S. net sales of more than $1B from the therapy.
  • The company has a collaboration and license agreement with Otsuka Pharmaceutical for the development and commercialization of oral voclosporin in countries outside the U.S.
  • And ‘receiving 10% to 20% royalties on EU and Japanese net revenues will be meaningful’ for the company topline argues Seeking Alpha contributor Amit Ghate in a bullish thesis on the stock.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.